Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
10
CCCC Quote, Financials, Valuation and Earnings
Last price:
$2.03
Seasonality move
:
-24.32%
Day range:
$2.02 - $2.14
52-week range:
$1.09 - $4.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.80x
P/B ratio:
1.27x
Volume:
891.8K
Avg. volume:
1.7M
1-year change:
-46.44%
Market cap:
$196.7M
Revenue:
$35.6M
EPS (TTM):
-$1.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
$6.3M | -$0.39 | -13.46% | -19.68% | $11.14 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.28% | -4.28% | $182.07 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 234.42% | $14.83 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
NRIX
Nurix Therapeutics, Inc.
|
$13.4M | -$0.92 | -9.4% | -23.71% | $28.41 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
$2.03 | $11.14 | $196.7M | -- | $0.00 | 0% | 4.80x |
|
BIIB
Biogen, Inc.
|
$176.83 | $182.07 | $25.9B | 16.13x | $0.00 | 0% | 2.68x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
GTBP
GT Biopharma, Inc.
|
$0.83 | $8.00 | $8.9M | -- | $0.00 | 0% | 59.35x |
|
NRIX
Nurix Therapeutics, Inc.
|
$19.30 | $28.41 | $1.5B | -- | $0.00 | 0% | 19.03x |
|
PFE
Pfizer Inc.
|
$25.09 | $28.62 | $142.7B | 14.62x | $0.43 | 6.86% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
28.47% | 3.112 | 37.33% | 5.52x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
NRIX
Nurix Therapeutics, Inc.
|
13.18% | 2.105 | 7.87% | 5.21x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
$9.2M | -$23.7M | -45.67% | -60.62% | -210.86% | -$31.6M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
NRIX
Nurix Therapeutics, Inc.
|
$2.9M | -$91.4M | -51.1% | -55.52% | -1157.65% | -$60.1M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
C4 Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CCCC or BIIB?
Biogen, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of 19%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About CCCC or BIIB?
C4 Therapeutics, Inc. has a consensus price target of $11.14, signalling upside risk potential of 448.91%. On the other hand Biogen, Inc. has an analysts' consensus of $182.07 which suggests that it could grow by 2.96%. Given that C4 Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe C4 Therapeutics, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 BIIBBiogen, Inc.14 18 1 -
Is CCCC or BIIB More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock CCCC or BIIB?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or BIIB?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than Biogen, Inc.'s net income of $466.5M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 4.80x versus 2.68x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.4.80x -- $11.2M -$32.2M BIIBBiogen, Inc.2.68x 16.13x $2.5B $466.5M
-
Which has Higher Returns CCCC or FOLD?
Amicus Therapeutics, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of 10.24%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About CCCC or FOLD?
C4 Therapeutics, Inc. has a consensus price target of $11.14, signalling upside risk potential of 448.91%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 7.02%. Given that C4 Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe C4 Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is CCCC or FOLD More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock CCCC or FOLD?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or FOLD?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 4.80x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.4.80x -- $11.2M -$32.2M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns CCCC or GTBP?
GT Biopharma, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of --. C4 Therapeutics, Inc.'s return on equity of -60.62% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About CCCC or GTBP?
C4 Therapeutics, Inc. has a consensus price target of $11.14, signalling upside risk potential of 448.91%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 861.08%. Given that GT Biopharma, Inc. has higher upside potential than C4 Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than C4 Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is CCCC or GTBP More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock CCCC or GTBP?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or GTBP?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are larger than GT Biopharma, Inc. quarterly revenues of --. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 4.80x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.4.80x -- $11.2M -$32.2M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns CCCC or NRIX?
Nurix Therapeutics, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of -1094.77%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat Nurix Therapeutics, Inc.'s return on equity of -55.52%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M NRIXNurix Therapeutics, Inc.36.66% -$1.03 $428.7M -
What do Analysts Say About CCCC or NRIX?
C4 Therapeutics, Inc. has a consensus price target of $11.14, signalling upside risk potential of 448.91%. On the other hand Nurix Therapeutics, Inc. has an analysts' consensus of $28.41 which suggests that it could grow by 47.21%. Given that C4 Therapeutics, Inc. has higher upside potential than Nurix Therapeutics, Inc., analysts believe C4 Therapeutics, Inc. is more attractive than Nurix Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 NRIXNurix Therapeutics, Inc.12 1 0 -
Is CCCC or NRIX More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison Nurix Therapeutics, Inc. has a beta of 1.874, suggesting its more volatile than the S&P 500 by 87.383%.
-
Which is a Better Dividend Stock CCCC or NRIX?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nurix Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. Nurix Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or NRIX?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are larger than Nurix Therapeutics, Inc. quarterly revenues of $7.9M. C4 Therapeutics, Inc.'s net income of -$32.2M is higher than Nurix Therapeutics, Inc.'s net income of -$86.4M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while Nurix Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 4.80x versus 19.03x for Nurix Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.4.80x -- $11.2M -$32.2M NRIXNurix Therapeutics, Inc.19.03x -- $7.9M -$86.4M
-
Which has Higher Returns CCCC or PFE?
Pfizer Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of 21.32%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About CCCC or PFE?
C4 Therapeutics, Inc. has a consensus price target of $11.14, signalling upside risk potential of 448.91%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that C4 Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe C4 Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 PFEPfizer Inc.7 15 1 -
Is CCCC or PFE More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock CCCC or PFE?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or PFE?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 4.80x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.4.80x -- $11.2M -$32.2M PFEPfizer Inc.2.28x 14.62x $16.7B $3.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
29
CDNAF alert for Dec 30
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
